A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment
Latest Information Update: 19 Oct 2020
At a glance
- Drugs GS 4774 (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 29 Aug 2020 Results evaluating whether HBV-specific T cell characteristics could be used as measure of clinical and biological activity of the candidate immunotherapy, presented at The International Liver Congress 2020
- 28 Mar 2019 Results assessing the efficacy and safety of GS-4774 in viremic patients Chronic Hepatitis B and Who Are Currently Not on Treatment published in the Gastroenterology
- 13 Jun 2018 Status changed from active, no longer recruiting to completed.